Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Completed · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.

Key facts

Study ID

NCT00046488

Run by

Biogen

People needed

70

Starts

2002-09-01

Expected to finish

2010-03-01

Last updated by the study team

2013-09-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed IRB-approved informed consent.
• Greater than 18 years of age
• Proof of CD23+ CLL or small lymphocytic lymphoma (SLL)
• Progressive disease after at least 1 course of chemotherapy
• Acceptable hematologic status, liver function, renal function, and pulmonary function
• Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment

You may not qualify if…

• Previous exposure to IDEC-152 or other anti-CD23 antibodies
• Presence of HIV infection or AIDS
• Serious nonmalignant disease
• Active uncontrolled bacterial, viral or fungal infections.
• Clinically active autoimmune disease
• Pregnant or currently breast feeding

Where it is running

• Research Site — La Jolla, California, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — New Hyde Park, New York, United States
• Research Site — New York, New York, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.